Teva Pharma (TEVA) volatility increases on Mylan (MYL) granted FDA approval of Copaxone
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $39.05 +1.35%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -11.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -11.5%
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) October weekly call option implied volatility is at 70 from 40, October is at 56 from 41, November is at 57; compared to its 52-week range of 24 to 61 on Mylan (Nasdaq; MYL) was granted FDA approval of the first generic for Copaxone.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) call put ratio 1.7 calls to 1 put as share price down 0.79%
- SpaceX: targeting to launch Starship flight 14 early as Sep 28
- Pegasystems (PEGA) call put ratio 1 call to 3.9 puts with a focus on 210 contracts of October 30 puts
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
